Technology
Mynd Immersive: transforming senior care with VR

From transporting patients to live Frank Sinatra concerts and museum tours to creating shared experiences for patients and caregivers, Mynd Immersive is harnessing the power of VR to transform how we deliver senior care, particularly for those living with dementia.
While VR has transformed the world of gaming, it is also innovating the world of senior care.
Launched in 2016, Mynd Immersive has been developing VR care to enhance the lives of older adults, particularly people with dementia, their carers and families.
Initially hosting live VR music performances, the company has gone on to develop lightweight, ergonomic VR glasses designed with dementia patients in mind, has recently partnered with the US Veteran Association (VA) to offer VR as a prescription for veterans, and has embarked on a new collaboration that has seen the launch of the Great American Elderverse – a virtual reality environment for older adults.

Chris Brickler, CEO of Mynd Immersive, spoke to Age Tech World to tell us more about how VR can help dementia patients build connections and meaningful experiences to help improve their quality of life.
“We started with the idea of leveraging a platform like Oculus and adapting it for dementia care,” said Brickler.
“We believed that by integrating music therapy, which has well-established scientific benefits, into a 360-degree immersive experience, we could make a real difference. Instead of simply playing Fly Me to the Moon by Frank Sinatra for an 85-year-old grandmother with dementia, we could take her on a virtual night out, recreating live music performances in an engaging, interactive way.”
Mynd’s first prototype was a Frank Sinatra-themed experience, featuring a big band, a martini glass on the table, and an elaborate 1950s-style production with 50 performers in period attire, explains Brickler.
“My vision was to use technology in a novel and creative way that could genuinely enhance the human experience,” he said.
“Although we have expanded the applications and use cases for our work in elder care, our core mission has remained the same: to improve and enrich the lives of the growing population of older adults while enhancing their health and wellbeing.”
Mynd conducted the largest ever study on VR and ageing with Stanford University. Taking place across 17 senior living communities in 10 different states, the study found that 74 per cent of caregivers reported improved mood in residents after using Mynd, 79 per cent of the residents reported feeling more positive, and 57 per cent of older adults reported feeling less isolated from the outside world.

“We all know that improving someone’s mood is a key factor in overall mental health,” said Brickler.
“What we discovered was that VR did not just provide a temporary boost in mood during the experience itself, it also created a profound shift by lifting residents beyond the four walls of their daily existence.
“We refer to this as the “fifth quadrant”, where VR connects human consciousness with past memories, loved ones, and meaningful experiences. Using immersive design and technology, we transport people beyond their immediate surroundings.
“This could mean taking them on virtual travel experiences, bringing them to live music performances, or even recreating historical events.
“For example, the 50th anniversary of the Apollo 11 moon landing was a major milestone that many older adults followed closely at the time. However, for the vast majority of seniors, travelling to the NASA museum in Houston is simply not feasible.
“By creating a virtual museum tour, we were able to bring this experience to thousands of older adults who would never have had the chance to see it otherwise.
“The Stanford study reinforced this impact, particularly in terms of mood enhancement. What surprised us even more was the social benefit of VR. We were not expecting such high numbers, but nine out of 10 participants reported that VR improved their relationships with caregivers.
“This is a huge breakthrough for both us and the industry. There is often a significant generational gap between older adults and their caregivers, which can lead to a lack of shared experiences and conversation topics. VR creates a bridge between these generations, fostering connection, engagement, and socialisation on both sides.
“We are incredibly excited about the findings from the Stanford study, as they highlight the potential of VR not only as a tool for entertainment, but as a way to enhance mental wellbeing and social interaction.”
To improve accessibility of VR technology for older generations, in 2023 Mynd partnered with HTC VIVE to launch a pair of light weight, ergonomic immersive glasses that weigh just 189 grammes, without a bulky strap. Brickler explains this ergonomic shift significantly improved uptake among older adults.

“For an 85-year-old person, who may not have the neck strength to support a 600-gramme headset, our new lightweight glasses have made a major difference,” says Brickler.
“They allow users to fully engage with VR without discomfort. Most VR headsets are built for younger users and gamers, but they are simply not suitable for long-term use in elder care settings.”
More recently, Mynd has partnered with the Consumer Technology Association Foundation to launch the Great American Elderverse – a philanthropic initiative designed to bring immersive extended reality experiences to underserved, lower-income seniors

“Our goal is to ensure equitable access to the benefits of digital therapeutics, making these advancements available to those who need them most,” said Brickler.
“The programme is still in its early stages, but it is starting to gain momentum. The first donation came from a generous family in New York City and was made through our partner, the Consumer Technology Association Foundation, a non-profit organisation. This foundation allows large donors to contribute, and from those donations, we distribute our immersive technology to senior communities in need.
“It is an incredibly rewarding initiative because it enhances social connections, stimulates cognition, and improves emotional wellbeing.
“Sadly, many lower-income seniors do not have access to the advanced care options available in the private-pay sector. By providing this technology at a very low cost, we ensure it remains scalable and shareable.
“Once a community has a few headsets, everyone in that community can access our programmes, which is a fantastic benefit.”
Mynd currently provides subscription-based access to its headsets, content, training, along with support for professional clinical teams using Mynd VR, and will now begin focusing on rolling out access to its product for home use.
“The numbers in the United States are staggering in terms of how many older adults require care, and in many cases, the burden of care falls entirely on family members,” says Brickler.
“In response, we have developed a programme called Mynd Care. Caring for someone with dementia can be incredibly stressful, and Mynd Care provides both wellness tools for relaxation and training tools for caregivers. For example, our platform can help reduce stress and improve mood for younger caregivers looking after dementia patients.”
One of the key features of Mynd Care is its scalable training simulations for carers. Staff are able to experience 30 minute training sessions that simulate scenarios that dementia patients might go through.
“This is particularly useful for new caregivers who need to understand how to handle different situations effectively and compassionately,” says Brickler.
“There are specific approaches that work well in dementia care, and there are also things that should definitely be avoided. Mynd Care provides an accessible, repeatable training system that ensures caregivers are well prepared.”

Mynd’s work with the VA has also seen the creation of the largest location-based extended reality network in the country, with over 100 locations, focused on reducing pain and anxiety.
“Tens of thousands of veterans in living centres can now access and use our technology, which has been a truly rewarding and impactful project,” says Brickler.
“Healthcare providers are increasingly looking for non-pharmaceutical interventions across pain management, cognitive health, and mental wellbeing. The push to introduce alternative treatments with clinical evidence is where Mynd comes in.”
News
Insilico in US$66m deal for Parkinson’s drug
News
Nanoparticles target disease proteins in dementia

Scientists have developed a nanoparticle strategy to broaden which disease-causing proteins medicines can target, giving options for dementia and brain cancer.
A perspective outlines an approach designed to remove harmful proteins that drive disease. By broadening the proteins that can be treated, the technology could help tackle conditions such as dementia and brain cancer.
The work was led by chair professor in nanomedicine Bingyang Shi at the University of Technology Sydney, in collaboration with professor Kam Leong of Columbia University and professor Meng Zheng of Henan University.
Professor Shi said: “Proteins are essential for nearly every function in the body, but when they become mutated, misfolded, overproduced or build up in the wrong place, they can disrupt normal cell processes and trigger disease.
He added: “Many conditions, including cancer, dementia, and autoimmune disorders, are driven by abnormal proteins, and some have shapes or behaviours that make them particularly resistant to drug treatments.”
To tackle these challenges, the researchers created a type of engineered nanoparticle called nanoparticle-mediated targeting chimeras (NPTACs).
The particles are designed to recognise specific disease-associated proteins and promote their breakdown in the body.
Professor Shi said: “We have developed an efficient and flexible method to guide disease-causing proteins, whether inside or outside the cell, into the body’s natural recycling system, where they can be broken down and removed.”
Interest in targeted protein degradation has surged in recent years.
Companies such as Arvinas have attracted more than US$1bn in investment and formed partnerships with pharmaceutical firms including Pfizer, Bayer and Roche.
However, existing protein degradation technologies face limitations.
Challenges such as poor tissue penetration, unintended interactions with other proteins and complex chemical design have slowed their use, particularly for brain disorders and solid tumours.
Professor Shi said: “Our nanoparticle-based strategy overcomes these bottlenecks.”
The researchers say the NPTAC platform can enable degradation of both proteins inside and outside cells, offers tissue and disease-specific targeting including across the blood-brain barrier (the protective barrier around the brain), and has plug-and-play modularity to adapt to diverse protein targets.
They say it is scalable and clinically translatable, leveraging FDA-approved nanomaterials and industry-proven synthesis strategies, and can combine with diagnostic or therapeutic capabilities.
Protected by multiple international patents, NPTACs have shown preclinical results against targets such as EGFR (a protein often driving tumour growth) and PD-L1 (a protein that helps cancer cells evade the immune system).
Professor Shi said: “This progress paves the way for applications in oncology, neurology, and immunology. It changes how we think about nanoparticles, not only as delivery tools but also as active therapeutic agents.
He added: “With the targeted protein degradation market expected to surpass $10 billion USD by 2030, NPTACs provide a powerful platform for the next generation of smart, precision therapies.
“We are now seeking strategic industry partners to accelerate clinical development, licence applications across therapeutic fields, and prepare for regulatory approval.”
News
Exciva raises US$59.4m for Alzheimer’s therapy

Exciva has raised US$59.4m in series B funding to support a phase 2 trial of its Alzheimer’s therapy.
The clinical-stage biopharmaceutical company is developing treatments for behavioural symptoms associated with the condition.
Neuropsychiatric symptoms such as agitation and other behavioural symptoms affect up to 90 per cent of patients with severe Alzheimer’s disease, driving caregiver burden, healthcare utilisation and reduced quality of life.
The funding will support Exciva’s phase 2 clinical trial evaluating Deraphan, the company’s lead candidate for agitation in Alzheimer’s disease.
Agitation can include restlessness, pacing, aggression and emotional distress.
The trial will be conducted across the European Union, US and Canada.
François Conquet, CEO of Exciva, said: “We are very pleased that we were able to secure funding from both existing and new investors.
“This confirms that our product is very promising.
“The new proceeds will primarily be used to finance a Phase 2 study.
“This study will investigate the therapeutic potential of Deraphan for treating agitation in patients with Alzheimer’s.
“The clinical trial will take place in Europe, the United States, and Canada.
“If the Phase 2 study results are positive, this would be a significant advance for symptomatic treatment of patients with Alzheimer’s disease.”
The financing was co-led by EQT and Gimv, with participation from Fountain Healthcare Partners, LifeArc, Carma Fund and Modi Ventures, as well as returning investors Andera Partners and LBBW.
Following the investment, EQT will be represented by Philip Scheltens as a director and Juliette Lee as an observer to the board of the company.
News3 weeks agoFDA clears automated brain fluid device
News3 weeks agoAgetech World’s latest innovation & investment round-up
News3 weeks agoInsilico signs US$888m oncology deal with Servier
News2 weeks agoFood preservatives linked to increased diabetes and cancer risk, study finds
News2 weeks agoCaptioning glasses win AARP pitch at CES
News3 weeks agoUK bans junk food ads before 9pm to protect child health
News2 weeks agoInterview: GlycanAge launch first hospital-based tests
Insights3 weeks agoGlobal longevity initiative launches North American chapter





















